Development and evaluation of dexamethasone-loaded bioadhesive polymeric nanocapsules for mitigating cardiac and gastric adverse effects of free dexamethasone

Abstract

Abstract Purpose Despite having a wide range of therapeutic advantages, dexamethasone (DEXM)-free formulations have some negative side effects that manifest over time. Polymeric nanocapsules (PNCs) exhibit a core-shell structure that can encapsulate and control the release of drug products. Accordingly, the present study aimed to develop a new nanoparticulate system, PNCs, as drug nanocarriers of DEXM and to exemplify the difference in safety profile regarding the gastropathic and cardiopathic effects of DEXM PNCs versus free DEXM. Methods Dexamethasone-loaded alginate nanocapsules were prepared using the nanoprecipitation technique and evaluated for different parameters. In-vivo assessment of the safety profile of the DEXMs (free and PNCs) necessitated three animal groups: vehicle, free DEXM, and DEXM PNCs groups. Treatments with DEXM were administered intraperitoneally, once daily, for 7 days. Stomach and heart samples were investigated for tissue damage. Tissue insults were assessed via macroscopic, biochemical, histopathological, and immunohistochemical analyses. Results The selected PNCs exhibited a small particle size of 287 ± 7.5 nm, a zeta-potential of -21.06 ± 0.23 mV, an encapsulation efficiency of 91.53 ± 0.5%, and a prolonged release profile for up to 48 h as compared with a free drug. Gastric damage indicators showed more serious mucosal damage with free DEXM, hemorrhagic ulcers, and enhanced oxidative stress than the DEXM PNCs. Biomarkers of cardiac damage were significantly elevated with free DEXM and significantly lower in the DEXM PNCs group. Conclusion Dexamethasone was successfully encapsulated into polymeric nanocapsules of sodium alginate coating polymer. The developed alginate nanocapsules exhibited desirable parameters and a superior anticipated side effect profile regarding gastric and cardiac damage.